A new study showed that the use of “Tirzepatide” and hormonal treatment for menopause at the same time leads to an increase in weight loss in women who suffer from weight gain or obesity after menopause, compared to the use of Terzopatid treatment alone.
“Menopause” is a time point located 12 months after the last menstrual period for women. The menopause stage often begins between the ages of 45 and 55 years. It lasts about 7 years, but it can reach 14 years. The duration can depend on lifestyle factors such as smoking, and the age at which the cycle started.
During the pre -menopause period, the body’s production of estrogen and progesterone varies greatly, two hormones secreted by the ovary. Hormonal therapy can compensate for lost hormones.
The study was conducted by Mayo Clinic researchers in the United States, and the results of the study were presented on Saturday, July 12th at the annual meeting of the Endocrine Association in San Francisco, California, in the United States and wrote the Yorik Alert website.
“This data is the first to show that the combination of Terzopatid and hormonal treatment for menopause significantly increases the effectiveness of treatment in women after menopause,” said Dr. Regina Castaneda, a researcher in the endocrine department in Mayo Clinic in Jacksonville, Florida.
She added, “Previous studies conducted on Simajlotide have found similar results. The achievement of these results may indicate a second drug to treat obesity to a broader direction for the effectiveness of combining these two categories of medicines.”
Hormone change increases abdominal fat
Hormonal changes associated with menopause often leads to increased abdominal fat, decreased muscle mass, and a change in energy consumption, and this leads to weight gain, and exposes millions of women at risk of heart disease and other serious health problems.
The researchers conducted a realistic study using the electronic medical records of 120 women of post -menopause over a moderate period of 18 months to confirm the hypothesis that the simultaneous hormonal treatment for menopause enhances the effectiveness of the Terzbatid in weight loss in women after menopause.
The study included two groups: 40 women use hormonal therapy for menopause in conjunction with the Terzbatid, and 80 women use Turzbatid alone.
The results showed a higher weight loss rate in women who use Turzbatid with hormonal treatment for menopause, compared to those who use Terzbatid alone.
“The information derived from this new study provides important visions to develop more effective and personal weight management interventions, with the aim of reducing the risk of women after menopause with weight gain and obesity health complications.
She added: “This study emphasizes the urgent need to conduct more research to better understand how obesity and hormonal therapy for menopause together. Gaining this knowledge would greatly improve the health and welfare of millions of women after menopause. It also indicates the need for better strategies to make these treatments more available to those who need them.”